Format

Send to

Choose Destination
Stem Cells Transl Med. 2017 Nov;6(11):2044-2052. doi: 10.1002/sctm.17-0081. Epub 2017 Sep 23.

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke.

Author information

1
Department of Neurology, University Medical Center Goettingen, Goettingen, Germany.
2
Department of Neurology, University of Duisburg-Essen Medical School, Essen, Germany.
3
Institute for Transfusion Medicine, University of Duisburg-Essen Medical School, Essen, Germany.

Abstract

Despite recent advances in stroke therapy, current therapeutic concepts are still limited. Thus, additional therapeutic strategies are in order. In this sense, the transplantation of stem cells has appeared to be an attractive adjuvant tool to help boost the endogenous regenerative capacities of the brain. Although transplantation of stem cells is known to induce beneficial outcome in (preclinical) stroke research, grafted cells do not replace lost tissue directly. Rather, these transplanted cells like neural progenitor cells or mesenchymal stem cells act in an indirect manner, among which the secretion of extracellular vesicles (EVs) appears to be one key factor. Indeed, the application of EVs in preclinical stroke studies suggests a therapeutic role, which appears to be noninferior in comparison to the transplantation of stem cells themselves. In this short review, we highlight some of the recent advances in the field of EVs as a therapeutic means to counter stroke. Stem Cells Translational Medicine 2017;6:2044-2052.

KEYWORDS:

Mesenchymal stem cells; Nervous system; Neural differentiation; Stem cell transplantation; Stem/progenitor cell

PMID:
28941317
DOI:
10.1002/sctm.17-0081
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center